Belgian Body Warns Over Price Erosion
More Than 3,000 Off-Patent Drugs Set For Price Cuts From April
With well over 3,000 off-patent medicines set for a price cut from the start of April in Belgium, local industry association Medaxes has voiced its support for government-led healthcare cost efficiencies but has warned of the risks of driving players out of the market with unsustainably low prices.
You may also be interested in...
Belgium’s Medaxes off-patent industry association has run a Generic Medicines Day to raise public awareness of the benefits of generics, as well as the obstacles that the industry faces.
Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.
Belgian body Medaxes is content with the latest pharmaceutical pricing legislation in the country, which cuts generics and biosimilars prices but also exempts such drugs from pharmaceutical clawback taxes.